Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
The von Hippel-Lindau (VHL) tumor suppressor is a substrate-defining component of E3 ubiquitin ligase complexes that target cellular substrates for proteasome-mediated degradation. VHL inactivation by mutation or transcriptional silencing is observed in most sporadic cases of clear cell renal ...
Haake and colleagues provide an overview of recent research on biomarkers to predict immunotherapy response in clear cell renal cell carcinoma and discuss the predictive and prognostic biomarkers to prioritize in this context.
During a live event, Daniel M. Geynisman, MD, and participants discussed their answers to a poll on which combination to use for a patient with advanced renal cell carcinoma.
The genetic risk of clear cell renal cell carcinoma is complex and the genes related are unclear. Here, the authors propose a deep reinforcement based model to identify risk genes.
Scott Tykodi, MD, PhD, discusses key clinical considerations that informing selection between IO/IO and IO/TKI combinations in advanced renal cell carcinoma.
In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
During a live event, Benjamin Garmezy, MD, discussed combinations regimens used for patients with renal cell carcinoma after immune checkpoint inhibitors.
The subcutaneous formulation of nivolumab showed comparable efficacy and safety to the IV formulation in advanced clear cell renal cell carcinoma.
Subcutaneous nivolumab demonstrated comparable efficacy, safety, and tolerability to IV nivolumab in advanced clear cell renal cell carcinoma.
The most notable progress in renal clear cell carcinoma (ccRCC) in the past decades is the introduction of drugs targeting the VHL-HIF signaling pathway-associated angiogenesis. However, mechanisms underlying the development of VHL mutation-independent ccRCC are unclear. Here we provide ...
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.